Methods for treating mitochondrial disorders

Abstract

To provide methods for the treatment of mitochondrial disorders.SOLUTION: The present disclosure provides pharmaceutical and nutraceutical compositions and methods for the treatment of mitochondrial disorders. The pharmaceutical or nutraceutical compositions include a stabilized sulforaphene, such as a sulforaphene-cyclodextrin complex, that increases the efficacy, biological activity and stability of isolated sulforaphene. The present disclosure also includes the use of stabilized sulforaphene as an effective therapeutic agent for the treatment of mitochondrial disorders, such as mitochondrial myopathy.SELECTED DRAWING: None

Description

[Technical field]

[0001] CITED RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 628,353, filed February 9, 2018, the entire contents of which are incorporated herein by reference.

[0002] Field of Disclosure The present disclosure provides pharmaceutical and nutraceutical compositions for use in treating mitochondrial disorders. More specifically, the present disclosure relates to a method for treating a subject with a mitochondrial disorder by administering a pharmaceutical or nutraceutical composition comprising a stable sulforaphene. [Background technology]

[0003] Background of the disclosure For example, certain constituents found in the seeds of vegetables of the Brassicaceae family, such as radish (Raphanus sativus), are known to have anti-cancer activity and anti-microbial properties. See PCT / US2006 / 010032. One such constituent, sulforaphane, is present in such plants in a bound form as glucoraphanin (a glucosinolate). In nature, sulforaphane, CH 11 NOS2 has the following chemical structure: [ka] and is formed from glucoraphanin after an enzymatic reaction. However, while much research has focused on the isolation and use of sulforaphane, other components (e.g., sulforaphene) have been overlooked due to their lack of solubility, bioavailability, and stability after isolation.

[0004] Mitochondrial disorders are diseases or defects that occur when mitochondria cannot generate adenosine 5-triphosphate (ATP) through oxidative phosphorylation. Mitochondria are essential organelles present in all mammalian cells. Briefly, mitochondria generate ATP from adenosine diphosphate (ADP) during cellular respiration by transferring electrons from NADH or FADH2 to O2 through electron carriers (a process known as the electron transport chain). Here, the energy released when electrons change from high-energy NADH or FADH2 to low-energy O2 is required to phosphorylate ADP and generate ATP. The energy used to generate ATP from ADP is governed by the electron transport chain and is generated by oxidative phosphorylation. The electron transport chain is essential to generate cellular energy and maintain cell viability. Thus, dysfunction in the mitochondrial electron transport chain results in reduced cellular ATP generation, increased anaerobic metabolism, and increased free radical generation, leading to oxidative stress and cell death.

[0005] Mitochondrial disorders can include one or more associated conditions (eg, abnormalities of: mitochondrial oxidative metabolism, aerobic metabolism, muscle weakness, fatigue, heart failure or dysfunction, limited mobility, and stroke).

[0006] Given the shortcomings associated with existing treatments and the increasing number of patients diagnosed with mitochondrial disorders, there is a need to develop new compositions and methods for the treatment of mitochondrial disorders. Summary of the Invention [Means for solving the problem]

[0007] Summary of disclosure The disclosed methods and compositions are based on the discovery that sulforaphene is a highly unstable, yet effective compound for the treatment of certain mitochondrial disorders when isolated from radish seeds. More specifically, the inventors have discovered that the efficacy and bioavailability of sulforaphene is severely reduced just a few days after isolation, a finding that precludes any potential therapeutic use of sulforaphene. However, the inventors have also discovered that pharmaceutical and nutraceutical compositions comprised of stable sulforaphene significantly improve the ability of sulforaphene to treat mitochondrial disorders by prolonging the bioactivity of sulforaphene and increasing cellular ATP production.

[0008] Thus, one aspect of the present disclosure provides a method for treating mitochondrial disorders, comprising administering to a subject a pharmaceutical or nutraceutical composition comprising stabilized sulforaphene.In some cases, the present disclosure provides a method for increasing mitochondrial function by increasing cellular ATP production through administering to a subject a pharmaceutical or nutraceutical composition comprising stabilized sulforaphene.

[0009] The disclosed methods include the use of a pharmaceutical or nutraceutical composition that includes stabilized sulforaphene. In some embodiments, the stabilized sulforaphene may be chemically modified to improve the solubility of the sulforaphene compound. In other embodiments, the sulforaphene may be stabilized by the presence of one or more solubilizing agents in the pharmaceutical or nutraceutical composition. In one embodiment, the stabilizer is a cyclodextrin, an alcohol, a glycol, a ketone, an oil, or a combination thereof.

[0010] In some embodiments, the pharmaceutical or nutraceutical composition comprises sulforaphene and a cyclodextrin. In certain embodiments, the cyclodextrin is one or more of alpha cyclodextrin, beta cyclodextrin, or gamma cyclodextrin.

[0011] In a preferred embodiment, the pharmaceutical or nutraceutical composition comprises sulforaphene and hydroxypropyl-β-cyclodextrin. Thus, in a specific embodiment, the method of the invention comprises administering to a subject a pharmaceutical composition comprising a complex of sulforaphene and hydroxypropyl-β-cyclodextrin (i.e., stabilized sulforaphene).

[0012] In one embodiment, the pharmaceutical or nutraceutical composition consists essentially of stabilized sulforaphene. In another embodiment, the composition consists essentially of sulforaphene complexed with a cyclodextrin (e.g., hydroxypropyl-β-cyclodextrin).

[0013] In some cases, the disclosure relates to a method that includes administering a pharmaceutical or nutraceutical composition to a subject. Administration can be, for example, oral, intravenous, intraperitoneal, or topical. In a specific embodiment, the subject is orally administered a pharmaceutical or nutraceutical composition that includes a stable sulforaphene composition. In other embodiments, the composition is administered to the subject by injection (e.g., by intravenous or intraperitoneal injection). In certain embodiments, the composition is administered orally as a pill, liquid, powder, or combination thereof.

[0014] In some embodiments, the subject being treated by the method of the present invention is a mammal. In certain embodiments, the subject is a human, mouse or rat. In one exemplary embodiment, the subject being treated is a human subject with mitochondrial disorder. In some cases, the subject being treated may show reduced mitochondrial function (e.g., ATP production). In a specific embodiment, the subject is a human who has been diagnosed with mitochondrial disorder, whereby the mitochondrial disorder affects the subject's ability to generate ATP through mitochondrial oxidative phosphorylation. Mitochondrial disorder may include one or more associated conditions (e.g., abnormalities: mitochondrial oxidative metabolism, aerobic metabolism, muscle weakness, fatigue, heart failure or dysfunction, mobility restriction and stroke).

[0015] Exemplary mitochondrial disorders that may be treated by the methods of the present invention include, but are not limited to, mitochondrial myopathies, essential tremor, Parkinson's disease, metabolic disorders resulting in abnormal metabolism of carbohydrates, lipids (fats), proteins, and / or nucleic acids by a subject, such as mitochondrial diabetes, chronic fatigue syndrome (CFS), skin aging, prostate disease (e.g., benign prostatic hyperplasia (BPH), hyperthyroidism, impaired glucose tolerance, hypercholesterolemia, dyslipidemia, hyperinsulinemia, thyroid dysfunction, multiple sclerosis, polycystic ovary syndrome (PCOS), psoriasis, and coronary artery disease.

[0016] In one embodiment, the mitochondrial disorder being treated by administration of solubilized sulforaphene is a mitochondrial myopathy. In a specific embodiment, the method of the disclosure comprises orally administering to a subject diagnosed with a mitochondrial myopathy an effective amount of a pharmaceutical or nutraceutical composition comprising a complex of sulforaphene and hydroxypropyl-β-cyclodextrin.

[0017] In other embodiments, the methods of the disclosure include orally administering to a subject diagnosed with essential tremor an effective amount of a pharmaceutical composition comprising a complex of sulforaphene and hydroxypropyl-β-cyclodextrin.

[0018] In another embodiment, the method of the disclosure comprises orally administering to a subject diagnosed with polycystic ovary syndrome (PCOS) an effective amount of a pharmaceutical composition comprising a complex of sulforaphene and hydroxypropyl-β-cyclodextrin.

[0019] In other embodiments, the disclosed methods include orally administering to a subject diagnosed with a skin disorder (e.g., psoriasis) an effective amount of a pharmaceutical composition comprising a complex of sulforaphene and hydroxypropyl-β-cyclodextrin. In some cases, the disclosed methods are used to treat a subject with psoriatic arthritis or skin aging by administering an effective amount of a pharmaceutical composition comprising a complex of sulforaphene and hydroxypropyl-β-cyclodextrin.

[0020] In other embodiments, the methods of the disclosure include orally administering to a subject diagnosed with chronic fatigue syndrome (CFS) an effective amount of a pharmaceutical composition comprising a complex of sulforaphene and hydroxypropyl-β-cyclodextrin. In certain embodiments, for example, the following are provided: (Item 1) 1. A method for treating a mitochondrial disorder, the method comprising: administering to a subject an effective amount of a stable sulforaphene composition, wherein the subject has a mitochondrial disorder, the stable sulforaphene composition comprising isolated sulforaphene and a stabilizing agent, wherein the administration effectively treats the mitochondrial disorder; The method includes: (Item 2) The method according to item 1, wherein the mitochondrial disorder is mitochondrial myopathy. 3. The method of claim 2, wherein the mitochondrial myopathy is selected from the group consisting of chronic fatigue syndrome, essential tremor, psoriasis, skin aging, polycystic ovary syndrome, mitochondrial diabetes, thyroid disease, prostatic hyperplasia, and multiple sclerosis. (Item 4) 4. The method of claim 3, wherein the mitochondrial myopathy is chronic fatigue syndrome, essential tremor, polycystic ovary syndrome, or psoriasis. (Item 5) 5. The method according to item 4, wherein the mitochondrial myopathy is chronic fatigue syndrome. (Item 6) 2. The method of claim 1, wherein the stable sulforaphene composition consists essentially of a sulforaphene / cyclodextrin complex. (Item 7) 7. The method of claim 6, wherein the sulforaphene / cyclodextrin complex is a complex of sulforaphene and hydroxypropyl-β-cyclodextrin. (Item 8) 7. The method of claim 6, wherein the cyclodextrin is a beta cyclodextrin or a hydroxyalkyl derivative thereof. (Item 9) 2. The method of claim 1, wherein the stable sulforaphene composition is administered as a pharmaceutical formulation or a nutraceutical composition. (Item 10) 10. The method of claim 9, wherein the pharmaceutical or nutraceutical composition is administered orally, by injection, or topically. (Item 11) 11. The method of claim 10, wherein the pharmaceutical or nutraceutical composition is administered orally. (Item 12) 10. The method of claim 9, wherein the pharmaceutical or nutraceutical composition is a powder, pill, or liquid formulation. (Item 13) 2. The method of claim 1, wherein the subject is a human. (Item 14) 14. The method of any one of items 6 to 13, wherein the stable sulforaphene composition is administered to the subject at least once a day. (Item 15) 15. The method of claim 14, wherein the stable sulforaphene composition is administered to the subject twice daily for at least two weeks. (Item 16) 1. A method for increasing ATP production in a cell, the method comprising: administering a stable sulforaphene composition to a cell, wherein said stable sulforaphene composition comprises isolated sulforaphene and a stabilizing agent, said administering increasing ATP production by said cell when compared to a cell not administered the stable sulforaphene composition; The method includes: (Item 17) 17. The method of claim 16, wherein the stable sulforaphene composition consists essentially of a sulforaphene / cyclodextrin complex. (Item 18) 18. The method of claim 17, wherein the sulforaphene / cyclodextrin complex is a complex of sulforaphene and hydroxypropyl-β-cyclodextrin. (Item 19) 18. The method of claim 17, wherein the cyclodextrin is a beta cyclodextrin or a hydroxyalkyl derivative thereof. (Item 20) 17. The method of claim 16, wherein the stable sulforaphene composition is administered as a pharmaceutical formulation or a nutritional supplement composition. [Brief description of the drawings]

[0021] [Figure 1A-1B]Stabilized sulforaphene induces mitochondrial ATP production in skin cells. SK-MEL-31 human skin cells were cultured and plated in 96-well plates at a cell density of 15,000 cells / well. The cells were then treated with staurosporine (STSP), a known inhibitor of mitochondrial function and ATP production. After incubation with STSP, the cells were then treated with either 100 μM sulforaphene·hydroxypropyl-β-cyclodextrin complex (compound 1), 17.5 μg / μL of a stabilized sulforaphene composition isolated from radish seed extract (compound 2), or 17.5 μg / μL of a positive control known to induce ATP production (compound 3). The cells were then incubated for 4 hours (data not shown), 48 hours (A), or 72 hours (B). Skin cells treated with the stabilized sulforaphene composition for more than 4 hours showed an increase in mitochondrial function similar to that of cells treated with the positive control and significantly greater than that of cells treated with STSP alone.

[0022] [Figure 2A-2B] Stabilized sulforaphene induces mitochondrial ATP production in muscle. A204 human muscle cells were cultured and plated in 96-well plates at a cell density of 15,000 cells / well. The cells were then treated with staurosporine (STSP), a known inhibitor of mitochondrial function and ATP production. After incubation with STSP, the cells were then treated with either 100 μM sulforaphene·hydroxypropyl-β-cyclodextrin complex (compound 1), 17.5 μg / μL of a stabilized sulforaphene composition isolated from radish seed extract (compound 2), or 17.5 μg / μL of a positive control known to induce ATP production (compound 3). The cells were then incubated for 4 hours (data not shown), 48 hours (A), or 72 hours (B). Muscle cells treated with the stabilized sulforaphene composition showed an increase in mitochondrial function similar to that of cells treated with the positive control and significantly greater than that of cells treated with STSP alone.

[0023] [Figure 3A-3B] Stabilized sulforaphene induces mitochondrial ATP production in pancreatic cells. PANC-1 human pancreatic cells were cultured and plated in 96-well plates at a cell density of 15,000 cells / well. The cells were then treated with staurosporine (STSP), a known inhibitor of mitochondrial function and ATP production. After incubation with STSP, the cells were then treated with either 100 μM sulforaphene·hydroxypropyl-β-cyclodextrin complex (compound 1), 17.5 μg / μL of a stabilized sulforaphene composition isolated from radish seed extract (compound 2), or 17.5 μg / μL of a positive control known to induce ATP production (compound 3). The cells were then incubated for 4 hours (data not shown), 48 hours (A), or 72 hours (B). Pancreatic cells treated with the stabilized sulforaphene composition showed an increase in mitochondrial function similar to that of cells treated with the positive control and significantly greater than that of cells treated with STSP alone. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Detailed Description of the Disclosure Without being bound by any one particular theory, the method of the present invention is based on the discovery that sulforaphene becomes unstable and ineffective immediately after isolation of sulforaphene compound from plants of the Brassicaceae family, such as Raphanus sativus (radish), in which sulforaphene naturally forms.Furthermore, the present inventors have discovered that the active compounds in radish seed extract for the treatment of mitochondrial disorders stabilize sulforaphene.For example, as shown herein, stabilized sulforaphene improves mitochondrial ATP production when compared with radish seed extract, which results in increased cell viability and maintenance. The inventors have therefore determined that pharmaceutical and nutraceutical compositions comprised of stabilized sulforaphene (e.g., sulforaphene complexed with hydroxypropyl-β-cyclodextrin) extend the bioavailability of sulforaphene and significantly improve the ability of sulforaphene to treat mitochondrial disorders such as, for example, mitochondrial myopathies (e.g., chronic fatigue syndrome (CFS)), essential tremor, mitochondrial diabetes, PCOS, and skin disorders (e.g., psoriasis and aging skin).

[0025] Thus, the present disclosure provides methods for treating mitochondrial disorders comprising administering to a subject a pharmaceutical or nutraceutical composition comprised of stabilized sulforaphene.

[0026] The therapeutic methods of the present disclosure include administration of a pharmaceutical or nutraceutical composition that includes stabilized sulforaphene. The term "sulforaphene" or "raphanin" as used herein has the molecular formula CHNOS and the following structure: [ka] Sulforaphene is intended to mean a compound having the molecular formula CH. Sulforaphene has several known aliases (e.g., sulforaphen, sulphoraphen, 4-isothiocyanato-1-(methylsulfinyl)-1-butene, 4-methylsulfinyl-3-butenyl isothiocyanate). Sulforaphene has a known molecular weight of approximately 175.26 g / mol. Sulforaphene, as used herein, is not intended to include sulforaphane, which has a structure and activity different from that of sulforaphene. As noted above, sulforaphane has the molecular formula CH. 11 It has NOS2, which lacks a double bond between the first and second carbons of the molecule, also known as, for example, 1-isothiocyanato-4-[(R)-methylsulfinyl]-butane.

[0027] Sulforaphene is a vinylic sulfoxide generally having the structural formula RS(=O)-R', which serves as a Michael acceptor in organic chemistry. Vinyl sulfoxides are compounds that modulate anaerobic oxidative phosphorylation in mitochondria.

[0028] Sulforaphene is a naturally occurring compound found, for example, in the seeds of radish (Raphani semen) that is produced by hydrolysis of glucoraphenin (a glucosinolate) by myrosinase. Thus, in certain embodiments, sulforaphene can be isolated from certain root vegetables, such as radishes. Naturally occurring, isolated sulforaphene can also be purified for use in the methods of the invention.

[0029] The term "isolated," when used in reference to a compound such as sulforaphene, means that the compound has been removed from its naturally occurring environment or the environment in which the compound was formed and is substantially free of other molecular materials. "Substantially free" means that the isolated compound comprises at least 60%, 70%, 80%, 90%, or 95% (by dry weight or volume) of the composition or preparation. For example, an isolated sulforaphene composition can be substantially free of other compounds (proteins, lipids, collagen) or plant material from which the sulforaphene was obtained. That is, sulforaphene represents more than about 80% of the volume of the preparation, more than about 90% of the volume of the preparation, or more than about 95% of the volume of the preparation. The level of purification can be based on its intended use.

[0030] Methods for isolating and purifying sulforaphene from radish seeds are known to those of skill in the art, and any such methods can be used herein. For example, radish seeds can be isolated and purified using the method described in West, L. et al., J Agric. Food Chem. (2004) 52, pp. 916-926, the entire contents of which are incorporated by reference, prior to forming the aqueous extract. Here, the plant or parts thereof may be ground, crushed, or blended prior to or simultaneously with the addition of the aqueous extract. Extraction of sulforaphene may be performed with water or water containing an organic solvent (e.g., ethyl alcohol). Specifically, in some cases, an aqueous extract of a cruciferous plant is formed by contacting the cruciferous plant seed with water having a temperature of 60-110° C. for at least 5 minutes. The aqueous extract may then be contacted with an adsorbent (e.g., activated carbon, silica, chemically modified silica, bleaching clay, etc., and mixtures thereof) that preferentially adsorbs sulforaphene instead of other compounds in the extract. Once the desired compound is adsorbed, it may be isolated from higher molecular weight proteins or compounds.

[0031] In other embodiments, the sulforaphene can be produced synthetically (such as by click chemistry, combinatorial chemistry, cycloaddition reactions, or solid phase synthesis), however, other known methods for forming synthetic sulforaphene are readily known by one of skill in the art.

[0032] As noted above, the pharmaceutical or nutraceutical compositions of the present disclosure include "stabilized sulforaphene." As used herein, "stabilized sulforaphene" or "stable sulforaphene" are used interchangeably herein to mean a sulforaphene compound or a sulforaphene-containing compound (e.g., a complex) that is more bioactive than naturally isolated sulforaphene over time. Biological activity can be determined by methods known to those of skill in the art (e.g., cell culture assays, in vivo studies, receptor binding assays, spectrophotometry, etc.). In certain cases, sulforaphene is stabilized by altering its chemical structure by known methods (e.g., such as modifying a side group, modifying the charge of the molecule, or adding a methyl group). In other cases, the sulforaphene is stabilized through the use of a stabilizing agent.

[0033] The term "agent" as used herein refers to any type of composition or combination of compositions. In one embodiment of the disclosure, the agent is a small molecule. In another embodiment of the disclosure, the agent is a biological molecule, including but not limited to a protein, a polypeptide, an antibody, or a nucleic acid. In certain embodiments, the stabilizer is a cyclodextrin, an alcohol, a glycol, a ketone, an oil, or a combination thereof. In a specific embodiment, the stabilized sulforaphene comprises a complex of sulforaphene and a stabilizer. In one exemplary embodiment, the stabilizer is hydroxypropyl-β-cyclodextrin.

[0034] In some embodiments, the pharmaceutical or nutraceutical composition comprises a stabilized sulforaphene that is a sulforaphene / cyclodextrin complex. The cyclodextrin can be one or more of alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin, or hydroxyalkyl derivatives thereof.

[0035] In specific embodiments, the pharmaceutical or nutraceutical composition comprises a stabilized sulforaphene selected from one or more of the following sulforaphene / cyclodextrin complexes: sulforaphene and beta cyclodextrin, or a hydroxyalkyl derivative thereof.

[0036] In one embodiment, the pharmaceutical or nutraceutical composition may consist essentially of stabilized sulforaphene, which is intended to mean that the only essential element of the composition is stabilized sulforaphene (i.e., the active agent). In another embodiment, the pharmaceutical composition consists essentially of stabilized sulforaphene, whereby the stabilized sulforaphene is sulforaphene complexed with a cyclodextrin or a hydroxyalkyl derivative thereof, which is intended to mean that the only essential elements of the composition are sulforaphene (i.e., the active agent) and cyclodextrin.

[0037] In yet other embodiments, the composition consists essentially of stabilized sulforaphene, whereby the stabilized sulforaphene is sulforaphene complexed with β-cyclodextrin or a hydroxyalkyl derivative thereof, which is intended to mean that the only essential elements of the composition are sulforaphene (i.e., the active agent) and β-cyclodextrin. While these pharmaceutical compositions may include other elements (e.g., additives or solvents), such other elements may be readily substituted with other similar or equivalent elements.

[0038] In one exemplary embodiment, the pharmaceutical or nutraceutical composition comprises a stabilized sulforaphene / cyclodextrin complex consisting of hydroxypropyl-β-cyclodextrin and sulforaphene.

[0039] In some embodiments, the methods of the invention utilize a pharmaceutical or nutraceutical composition comprising stabilized sulforaphene that is greater than 75% pure sulforaphene, greater than 80% pure sulforaphene, greater than 85% pure sulforaphene, greater than 90% pure sulforaphene, greater than 95% pure sulforaphene, or greater than 99% pure sulforaphene. In some cases, the molar ratio of the stabilized sulforaphene to other components of the pharmaceutical composition is within the range of 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, or greater.

[0040] The pharmaceutical or nutraceutical composition comprising stabilized sulforaphene and cyclodextrin can be formed by mixing the sulforaphene or a natural source thereof with cyclodextrin in a suitable solvent to form a precipitate. Any suitable solvent known in the art can be utilized. In certain cases, the solvent is an aqueous solvent including water and optionally one or more water-miscible solvents (e.g., ethanol). In other cases, the solvent is water, dissolving the cyclodextrin in the solvent can be accomplished by any dissolution method known in the art. For example, the cyclodextrin can be fully or partially dissolved in the solvent by placing the cyclodextrin in the solvent and heating the mixture. In another example, sonication can be utilized to either fully or partially dissolve the cyclodextrin in the solvent. Once the sulforaphene and cyclodextrin are combined in solution, they can be mixed and cooled to form a precipitate (stabilized sulforaphene). The precipitate can then be filtered to obtain a stable sulforaphene-cyclodextrin complex.

[0041] In some embodiments, the methods of the invention utilize a pharmaceutical composition comprising sulforaphene in its cyclodextrin complex that is greater than 75% pure sulforaphene, greater than 80% pure sulforaphene, greater than 85% pure sulforaphene, greater than 90% pure sulforaphene, greater than 95% pure sulforaphene, or greater than 99% pure sulforaphene. In some cases, the molar ratio of sulforaphene to cyclodextrin in the resulting complex is within the range of 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9: or greater. In specific examples, the ratio of sulforaphene to cyclodextrin is 0.8:1 to 1:1, 0.9:1 to 1:1, 0.95:1 to 1:1, or 0.98:1 to 1:1.

[0042] In some embodiments, the pharmaceutical composition is formulated as a unit dose composition, e.g., tablet, powder, or liquid, and may contain about 0.1% to 100%, 0.1% to 90%, 0.1% to 80%, 0.1% to 70%, 0.1% to 60%, 0.1% to 50%, 0.1% to 40%, 0.1% to 30%, 0.1% to 20%, or 0.1% to 10% by weight of the active compound (i.e., stabilized sulforaphene). In one embodiment, the pharmaceutical composition contains 5.0% to 30%, 10% to 25%, or 10% to 20% stabilized sulforaphene. In a specific embodiment, the pharmaceutical composition contains 10% to 22% stabilized sulforaphene.

[0043] In certain non-limiting embodiments, the pharmaceutical or nutraceutical compositions of the present disclosure comprise stabilized sulforaphene and at least one additive. In specific embodiments, the pharmaceutical composition comprises a stabilized sulforaphene / cyclodextrin complex and at least one additive. The additives may include carriers, stabilizers, antioxidants, colorants, diluents, and excipients that do not alter the performance of sulforaphene to such an extent that treatment is ineffective.

[0044] Exemplary carriers include, but are not limited to, saline, Ringer's solution, phosphate solution or buffer, buffered saline, and other carriers known in the art. The carriers may be solid or liquid, or both, and may be formulated with the pharmaceutical composition as a unit dose composition (e.g., tablet, powder, or liquid), which may contain about 0.1% to 100% by weight, 0.1% to 90% by weight, 0.1% to 80% by weight, 0.1% to 70% by weight, 0.1% to 60% by weight, 0.1% to 50% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1% to 20% by weight, or 0.1% to 10% by weight of the active compound (i.e., stabilized sulforaphene). In one embodiment, the pharmaceutical composition contains 5.0% to 30% by weight, 10% to 25% by weight, or 10% to 20% by weight of stabilized sulforaphene. In a specific embodiment, the pharmaceutical composition comprises 10% to 22% stabilized sulforaphene by weight.

[0045] The pharmaceutical or nutraceutical composition can be formulated based on the desired route of administration of the stabilized sulforaphene.The desired route of administration can be one or more of oral, enteral, parenteral, injection, buccal, and topical.For example, in one embodiment, the composition is suitable for oral administration.In some embodiments, the composition includes a carrier and / or additive suitable for facilitating delivery of the composition to the skin, intestine, or bloodstream of a subject.

[0046] In particular, the pharmaceutical or nutraceutical compositions of the present disclosure, or the formulations in which they are included, can be orally administered, for example, as tablets, coated tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.The compositions intended for oral use can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions can contain one or more additives selected from the group consisting of sweeteners, flavoring agents, coloring agents and preservatives, in order to provide medicament-acceptable and palatable preparations.

[0047] The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period, for example, a time delay material such as glyceryl monostearate or glyceryl distearate may be used.

[0048] The pharmaceutical or nutraceutical compositions of the present disclosure may also contain non-toxic excipients, such as inert diluents (e.g., calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate); granulating and disintegrating agents (e.g., corn starch or alginic acid); binding agents (e.g., starch, gelatin, or gum acacia), and lubricants (e.g., magnesium stearate, stearic acid or talc).

[0049] The pharmaceutical or nutraceutical compositions may also be formulated as hard gelatin capsules in which the active ingredient (stabilized sulforaphene, e.g., sulforaphene / cyclodextrin complex) may be mixed with an inert solid diluent, such as, for example, calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules in which the active ingredient is present with or mixed with water or an oil medium, such as, for example, peanut oil, liquid paraffin, any of a variety of herbal extracts, milk, or olive oil.

[0050] Aqueous suspensions can be produced, which contain the active ingredient (stabilized sulforaphene) in admixture with excipients suitable for the manufacture of aqueous suspensions.Such excipients include suspending agents (such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, and gum acacia); dispersing or wetting agents can be naturally occurring phosphatides (such as lecithin), or condensation products of alkylene oxides with fatty acids (such as polyoxyethylene stearate), or condensation products of ethylene oxide with long-chain aliphatic alcohols (such as heptadecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters obtained from fatty acids and hexitols (such as polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters obtained from fatty acids and hexitol anhydrides (such as polyoxyethylene sorbitan monooleate).

[0051] The aqueous suspensions may also contain one or more preservatives (such as, for example, ethyl or n-propyl p-hydroxybenzoate), one or more coloring additives, one or more flavoring additives, or one or more sweetening agents (such as sucrose, glycerol, sorbitol or saccharin).

[0052] Oil suspensions can be formulated by suspending the active ingredient (stabilized sulforaphene, e.g., sulforaphene / cyclodextrin complex) in omega-3 fatty acids, vegetable oils (such as peanut oil, olive oil, sesame oil, or coconut oil), or in mineral oils (such as liquid paraffin). The oil suspensions can contain thickening additives (such as beeswax, hard paraffin, or cetyl alcohol).

[0053] Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.

[0054] Dispersible powders and granules suitable for preparing pharmaceutical compositions by adding water provide the active ingredient (stabilized sulforaphene) in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives.Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.Additional excipients (e.g., sweeteners, flavoring agents and coloring agents) may also be present.

[0055] Syrups and elixirs containing the stable sulforaphane (e.g., sulforaphane / cyclodextrin complex) may be formulated with sweeteners (such as, for example, glycerol, sorbitol, or sucrose). Such formulations may also contain demulcents, preservatives, and / or flavoring and coloring agents. Liquid dosage forms for oral administration may include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, and / or elixirs containing inert diluents commonly used in the art (e.g., water). Such compositions may also contain adjuvants (e.g., wetting agents, emulsifying and / or suspending agents), as well as sweeteners, flavoring agents, and / or perfuming agents.

[0056] Pharmaceutical or nutraceutical compositions suitable for oral administration may be presented in separate units (each containing a predetermined amount of stabilized sulforaphene to effect treatment); as a powder or granules; as a liquid or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As indicated, such compositions may be prepared by any suitable method of pharmacy, which may include the step of bringing into association the active ingredient (stabilized sulforaphene, e.g., sulforaphene / cyclodextrin complex) and the carrier (which may constitute one or more additives).

[0057] For example, a tablet can be prepared by compressing or molding a powder or granules of stabilized sulforaphene, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the compound (e.g., powder or granules) in a free-flowing form, optionally mixed with a binder, lubricant, inert diluent and / or surfactant / dispersant(s). Molded tablets can be made by molding in a suitable machine the powdered compound moistened with an inert liquid diluent.

[0058] The pharmaceutical or nutraceutical compositions of the present disclosure may be coated or uncoated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a delayed action over a longer period of time. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be used.

[0059] The composition for use in the method of the present invention can be an injection.For example, the pharmaceutical composition can be a sterile injection solution or suspension in a non-toxic parenterally acceptable diluent or solvent (such as a solution in 1,3-butanediol).Among the acceptable vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution.In addition, sterile fixed oils are conventionally used as a solvent or suspension medium.For this purpose, any non-irritating fixed oil can be used, including synthetic mono- or diglycerides.In addition, n-3 polyunsaturated fatty acids can be used in the preparation of injections.

[0060] Pharmaceutical and nutraceutical compositions may also include sterile aqueous preparations prepared by mixing the stable sulforaphene with water and rendering the resulting solution sterile and isotonic with blood. Injectable pharmaceutical compositions according to the invention generally contain 5%-40% w / w of the stable sulforaphene.

[0061] The injectable compositions may also contain saline, dextrose, or water as a suitable carrier. Appropriate doses of stabilized sulforaphene, such as sulfuraphene / cyclodextrin complexes, are those that achieve relatively the same serum levels as those described above.

[0062] The pharmaceutical compositions of the present disclosure may also be topical preparations for the skin and may take the form of an ointment, cream, lotion, paste, gel, spray, powder, jelly, colyrium, solution, suspension, aerosol, or oil. Carriers may be used, including petrolatum (e.g., Vaseline®), lanolin, polyethylene glycols, alcohols, and combinations of two or more of these. The active ingredient (stabilized sulforaphene, e.g., sulforaphene / cyclodextrin complex) is generally present in a concentration of about 0.1% to 100%, 0.1% to 90%, 0.1% to 80%, 0.1% to 70%, 0.1% to 60%, 0.1% to 50%, 0.1% to 40%, 0.1% to 30%, 0.1% to 20% or 0.1% to 10% by weight of the active compound, i.e., stabilized sulforaphene. In one embodiment, the pharmaceutical composition comprises 5.0% to 30%, 10% to 25% or 10% to 20% stabilized sulforaphene. In a specific embodiment, the pharmaceutical composition comprises 10% to 22% stabilized sulforaphene.

[0063] The pharmaceutical and nutraceutical compositions of the present invention may also contain safe and effective amounts of isotonicity agents, including salts (e.g., sodium chloride), and / or non-electrolyte tonicity agents (e.g., sorbitol and mannitol).

[0064] The pharmaceutical and nutraceutical compositions of the present invention may also be enhanced by the incorporation of surfactants or co-solvents. Such co-solvents may include polysorbates 20, 60, and 80, polyoxyethylene / polyoxypropylene surfactants (e.g., Pluronic F-68, F-84, and P-103, available from BASF®), or other agents known to those skilled in the art. Such co-solvents may be used at levels of about 0.01% to about 2% by weight.

[0065] Effective formulation and administration procedures are well known in the art and are described in standard textbooks; see, for example, Gennaro, AR, Remington: The Science and Practice of Pharmacy, 20th edition, (Lippincott, Williams and Wilkins), 2000; Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1975; Liberman, et al., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Kibbe, et al., eds., Handbook of Pharmaceutical Excipients (3rd ed.), American Pharmaceutical Association, Washington, 1999.

[0066] As mentioned above, in certain embodiments, the stabilized sulforaphene is included in a nutraceutical composition. "Nutraceutical composition" as used herein means a multi-drug composition, whereby one drug is the stabilized sulforaphene and other drugs may target one or more different biochemical pathways to provide multiple therapeutic effects to a subject.

[0067] In some embodiments, the nutritional supplement composition comprises stable sulforaphene and at least one, at least two, at least three, at least four, at least five, or at least six, or more agents from the following groups, members of which have a therapeutic effect on one or more mammalian conditions (e.g., mitochondrial disorders): Group 1: minerals, vitamins, and dietary supplements; Group 2: herbal medicines; Group 2: dietary enzymes (such as, for example, bromelain and papain); Group 3: dietary enzymes (such as, for example, bromelain and papain); Group 4: fibre; Group 5: hydrolysed proteins; Group 6: phytonutrients (such as, for example, resveratrol); Group 7: carotenoids (such as, for example, lycopene); Group 8: prebiotics and probiotics.

[0068] In another embodiment, the nutritional composition comprises stable sulforaphene and at least one active ingredient from the above group. In a specific embodiment, the nutritional composition comprises stable sulforaphene and at least one active ingredient from the above group and is provided as a food additive such as a powder. In certain embodiments, the nutritional composition comprises a sulforaphene / cyclodextrin complex and at least one active ingredient from at least one of the above groups. In one embodiment, the nutritional composition comprises stable sulforaphene and at least one active ingredient from each of the above groups.

[0069] The methods of the invention include administering to a subject a nutritional supplement composition that includes stabilized sulforaphene, including, but not limited to, a sulforaphene / cyclodextrin complex. For example, administering to a subject a nutritional supplement composition comprised of a sulforaphene / hydroxypropyl-β-cyclodextrin complex.

[0070] Any method for preparing a nutritional supplement formulation can be used according to the method of the present invention.In some cases, the method for preparing the nutritional supplement composition of the present disclosure is the same or substantially the same as that used for preparing a pharmaceutical composition.In one embodiment, the nutritional supplement composition of the present disclosure is prepared by the same method used for preparing the above-mentioned pharmaceutical composition.In another embodiment, the nutritional supplement composition is formulated and administered according to the above-mentioned method.In yet another embodiment, the nutritional supplement composition of the present disclosure is prepared using a method known to those skilled in the art.

[0071] A "subject" is used interchangeably herein with the term "patient" and may be a human or any other mammal, including, but not limited to, a primate, rat, mouse, rabbit, pig, cow, sheep, goat, cat or dog. A "subject," as used herein, is any subject that has, in the judgment of a practitioner (e.g., clinician or veterinarian), a condition (direct, associated or otherwise) indicative of a mitochondrial disorder.

[0072] In some embodiments, the subject being treated by the method of the present invention is a mammal.In certain embodiments, the subject is a human, a mouse or a rat.In one exemplary embodiment, the subject being treated is a human subject with a condition that indicates mitochondrial disorder.In a specific embodiment, the subject is a human who has been diagnosed with mitochondrial disorder, whereby the mitochondrial disorder affects the subject's ability to metabolize carbohydrates, lipids (fats), proteins and / or nucleic acids and generate ATP.

[0073] In some cases, the subject has one or more of the following conditions associated with a mitochondrial disorder (eg, abnormalities in mitochondrial oxidative metabolism, reduced ATP production, and / or reduced cell viability).

[0074] Administration can be, for example, oral, intravenous, intraperitoneal, or topical. In a specific embodiment, the subject is administered a stable sulforaphene composition orally, while in other embodiments, the composition is administered to the subject by injection (e.g., by intravenous or intraperitoneal injection). In another embodiment, the pharmaceutical composition is administered topically.

[0075] In the methods of the present invention, a subject in need of treatment and / or prevention of one or more of the mitochondrial disorders or conditions thereof described herein may be treated by administration of an amount of a pharmaceutical or nutraceutical composition comprised of stable sulforaphene such that the amount of the active component(s) (stable sulforaphene, e.g., sulforaphene / cyclodextrin complex) provides a dosage or amount sufficient to constitute treatment or prevention of the mitochondrial disorder or symptoms thereof (i.e., an "effective amount").

[0076] As used herein, "effective amount" refers to a dose or amount of a pharmaceutical or nutraceutical composition comprising a stable sulforaphene administered to a subject that results in the reduction or eradication of a mitochondrial disorder or its symptoms. The effective amount of the composition can be readily determined by one skilled in the art by the use of known techniques and by observing results obtained under analogous circumstances.

[0077] In one exemplary embodiment, an effective amount of a pharmaceutical or nutraceutical composition comprising stable sulforaphene administered to a subject results in an increase in ATP production by cells of the subject.

[0078] The effective amount of a pharmaceutical or nutraceutical composition comprised of a stabilized sulforaphene (e.g., a sulforaphene / cyclodextrin complex) can depend on many factors, such as the particular stabilizer or method used, the subject, the mode of administration, and the disorder being treated. For example, the dosage can be adjusted based on the subject's weight, the subject's age and health, and the tolerance of the composition being administered.

[0079] Certain non-limiting examples of suitable dosage ranges for injection of pharmaceutical compositions include, but are not limited to, a dose of 0.06 mg / kg / day for individuals weighing 40 kg or less, which may be increased or decreased by 0.02 mg / kg to a maximum daily dose of 0.13 mg / kg (a dose of 2.5 mg / day) for individuals weighing more than 40 kg, which may be increased or decreased by 1.25 mg to 2.5 mg / day to a maximum dose of 10 mg / day for women weighing more than 40 kg, and a dose of 5 mg / day is appropriate, which may be increased or decreased by 1.25 mg to 2.5 mg / day to a maximum dose of 10 mg / day. In yet another example, the pharmaceutical compositions of the present disclosure may be delivered to a subject in a dose of 30 mcg / mL, 60 mcg / mL, 90 mcg / mL or 120 mcg / mL.

[0080] In other examples, the dosage of the compositions and methods of the present invention provided herein can be determined and adjusted based on its effectiveness in providing therapeutic effect.Furthermore, those skilled in the art know how to measure and quantify the presence or absence of mitochondrial disorder or its symptoms after treatment according to the method of the present invention.In some cases, the therapeutically effective amount improves or reduces one or more of the following abnormal conditions in a subject: mitochondrial oxidative metabolism, amino acid metabolism, organic acid metabolism, ATP production by cells (e.g., skin cells or muscle cells), cell viability, fatty acid metabolism, carbohydrate metabolism, uric acid formation and peroxisomal metabolism.

[0081] For example, in the case of mitochondrial myopathy (e.g., chronic fatigue syndrome or essential tremor), an effective amount of stable sulforaphene reduces or eliminates irregularities in cellular metabolism, increases mitochondrial function (i.e., ATP production), increases excretion of one or more amino acids, or any combination of the foregoing conditions.

[0082] In the case of skin disorders (eg, psoriasis, aging skin, or psoriatic arthritis), effective treatment may improve skin lesions or inflammation.

[0083] In the case of PCOS, effective treatment with a stable sulforaphene / cyclodextrin complex reduces or eliminates in a subject one or more of the following: irregular menstruation, abnormal androgens, polycystic ovaries or related conditions as set forth below.

[0084] Effective doses can also be extrapolated from dose-response curves derived from in vitro or animal model systems (e.g., in mouse models).Those skilled in the art will appreciate that dosages can also be determined with the guidance of Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition (1996), Appendix II, pp. 1707-1711.

[0085] The pharmaceutical or nutraceutical composition of the present disclosure can be administered once or multiple times per day if necessary.Dosage frequency can vary from a single dose per day to multiple doses per day.In one embodiment, the composition can be administered once a week, once every two weeks, once every three weeks, once a month, once every two months, or twice a year.In some embodiments, the composition can be administered, for example, when the subject with mitochondrial disorder shows inflammation, skin lesions, muscle tremors, fatigue, or other symptoms that warrant treatment administration.

[0086] The methods of the present invention include treatment of mitochondrial disorders.

[0087] The term "treatment" refers to the prevention or amelioration of mitochondrial disorder or one or more symptoms thereof in a patient or subject. "Treating" a mitochondrial disease is not intended to require the disease to be completely cured or eradicated. The treatment need only reduce or inhibit the disorder, i.e., have a "therapeutic effect". Similarly, the progression of a disorder is considered herein to be "reduced" or "inhibited" if, in the judgment of the practitioner, one or more of the characteristic signs of the progression of the disorder are reduced or inhibited. The term "therapeutic effect" refers to the inhibition, activation or replacement of factors that cause or contribute to a mitochondrial disorder or its symptoms in a subject, such as, for example, a mitochondrial myopathy, a skin disorder, a muscle disorder or a metabolic disorder (e.g., type 2 diabetes).

[0088] The term "mitochondrial disorder" or "mitochondrial disease" is used interchangeably herein to refer to disorders or defects that occur when a subject's cells cannot properly metabolize carbohydrates, lipids (fats), proteins, or nucleic acids by oxidative phosphorylation. Thus, in the context of the method of the present invention, any disorder related to the abnormality of a subject's ability to generate ATP is encompassed within the term "mitochondrial disorder". Examples of mitochondrial disorders include, but are not limited to, mitochondrial myopathy, metabolic disorders, skin disorders, prostate disorders, or disorders of the central nervous system. For the purposes of this disclosure, metabolic disorders are not intended to include cancer.

[0089] Exemplary mitochondrial disorders that can be treated by the method of the present invention include, but are not limited to, mitochondrial myopathy.As used herein, the term "mitochondrial myopathy" refers to the dysfunction in the generation of ATP by mitochondrial oxidative phosphorylation by muscle cells and / or cells of the central nervous system (CNS) of a subject.Symptoms of mitochondrial myopathy include muscle weakness or exercise intolerance, heart failure or rhythm abnormalities, dementia, movement disorders, stroke-like episodes, hearing loss, blindness, ptosis, limited eye mobility, vomiting, and seizures.Some exemplary mitochondrial myopathy, which can be treated by administering an effective amount of sulforaphene / hydroxypropyl-β-cyclodextrin complex, include, but are not limited to, chronic fatigue syndrome (CFS), prostate disease (i.e., prostatic hyperplasia), essential tremor, Parkinson's disease, and multiple sclerosis.

[0090] In an exemplary embodiment, a subject to whom a composition consisting of stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) has been administered in accordance with the present disclosure has a mitochondrial myopathy, such as chronic fatigue syndrome (CFS). "Chronic fatigue syndrome (CFS)" as used herein means a mitochondrial disorder that manifests as prolonged physical and mental fatigue. CFS is associated with one or more of the following symptoms: pain and increased sensitivity, abnormal metabolism (e.g., energy metabolism, amino acid metabolism, nucleotide metabolism, nitrogen metabolism, hormone metabolism, and oxidative stress metabolism), reduced mitochondrial function, reduced excretion of amino acids and nitrogen by cells. A subject can be readily diagnosed with CFS by one of skill in the art using known methods to detect changes in mitochondrial cellular metabolism (e.g., ATP production or cell viability by using metabolomics).

[0091] In an exemplary embodiment, a subject to whom a composition consisting of stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) is administered in accordance with the present disclosure has a mitochondrial myopathy, such as prostate disease. "Prostatic hyperplasia" or "prostate disease" are used interchangeably herein to mean a mitochondrial disorder that manifests as an enlarged prostate (e.g., present in "benign prostatic hyperplasia (BPH)"). Prostatic hyperplasia is associated with one or more of the following symptoms: reduced or obstructed flow of urine from the bladder, frequent urination, inability to empty the bladder, urinary tract infection, or hematuria. A subject can be readily diagnosed with BPH by one of skill in the art using known methods to detect changes in mitochondrial cellular metabolism (e.g., ATP production or cell viability by using metabolomics).

[0092] Mitochondria play an essential role in providing the energy required for dopaminergic neurons to function properly.Thus, in some embodiments of the present disclosure, the subject to which the composition comprising stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) is administered has central nervous system mitochondrial myopathy.Exemplary central nervous system mitochondrial myopathy includes, but is not limited to, essential tremor, multiple sclerosis, dementia and Parkinson's disease.

[0093] In an exemplary embodiment, a subject to whom a composition consisting of stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) is administered in accordance with the present disclosure has a mitochondrial myopathy, such as essential tremor. The term "essential tremor" as used herein means a neurological disorder that causes involuntary and rhythmic shaking of the extremities. Essential tremor is evident when the hands, head, or voice shake involuntarily during use, or when the subject exhibits an abnormal gait.

[0094] In one embodiment, a subject to whom a composition comprising stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) is administered in accordance with the present disclosure has a mitochondrial myopathy, such as multiple sclerosis (MS). The term "multiple sclerosis" as used herein refers to a neurodegenerative disorder caused by abnormalities in mitochondrial oxidative phosphorylation resulting in reduced ATP production, leading to axonal injury, neuronal loss (reduced cell viability), and atrophy of the central nervous system.

[0095] Mitochondrial function also regulates hormone production by the endocrine system. The thyroid gland is located in the front of the neck and secretes two types of thyroid hormones: T4 (thyroxine) and T3 (triiodothyronine). Thyroid hormones are known to regulate the basal metabolic state and oxidative metabolism of cells. For example, thyroid hormones are associated with oxidative stress and antioxidant status due to their ability to alter oxidative respiration in mitochondria. In addition, the thyroid gland can produce hormones that signal oxidative stress that results in reduced ATP production by mitochondria and thus cell death. Such oxidative stress is present, for example, in polycystic ovarian syndrome (PCOS), mitochondrial diabetes, hypothyroidism and hyperthyroidism.

[0096] Thus, in an exemplary embodiment, a subject to whom a composition comprising stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) is administered in accordance with the present disclosure has PCOS. "Polycystic ovarian syndrome" as used herein means a mitochondrial disorder present in female subjects with one or more of the following symptoms: irregular menstruation, abnormal androgens, and polycystic ovaries. PCOS also presents with other common disorders ("associated symptoms or conditions") such as insulin resistance, obesity, impaired glucose tolerance, dyslipidemia, and / or hypertension.

[0097] Mitochondria play an essential role in providing the energy required for skin cells to function properly. Thus, in some embodiments of the present disclosure, a subject to whom a composition comprising stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) is administered has cutaneous mitochondrial myopathy. Exemplary cutaneous mitochondrial myopathy includes, but is not limited to, psoriasis, psoriatic arthritis, and cutaneous aging.

[0098] Thus, in one embodiment, a subject to whom a composition comprising stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) is administered in accordance with the present disclosure has a mitochondrial myopathy, such as psoriasis. The term "psoriasis" as used herein refers to a Th-1 and Th-17 mediated disease associated with mitochondrial disorders. Psoriasis is characterized by inflammation, irritation, scaling of the skin and one or more of the following: dry lesions, stiff or swollen joints, obesity, hypertension, dyslipidemia, and insulin resistance disorders.

[0099] In another embodiment, a subject to whom a composition consisting of stabilized sulforaphene (e.g., sulforaphene / hydroxypropyl-β-cyclodextrin complex) is administered in accordance with the present disclosure has a mitochondrial myopathy, such as aging skin. The term "aging skin" as used herein means the progressive structural and functional degeneration of the epidermis of the skin. Aging skin is primarily caused by an increase in reactive oxygen species (ROS) as a by-product of mitochondrial cellular metabolism. ROS, in turn, cause damage to important cellular components such as membranes, enzymes, and deoxyribonucleic acid (DNA), resulting in cell death. Furthermore, in aging skin, the cell proliferation rate decreases in the epidermis, inducing a steady deterioration of the structure and function of the skin. Aging skin may be a precursor to other skin disorders, such as eczema, dermatitis, keratosis, and various forms of neoplasia, such as basal and squamous cell carcinomas and malignant melanoma.

[0100] Other embodiments within the scope of the claims herein will be apparent to those skilled in the art from consideration of the specification and practice of the methods as disclosed herein. It is intended that the specification and experimental results below be considered as exemplary only, with the scope and spirit of the invention being indicated by the following claims. EXAMPLES

[0101] Example 1. Materials and Methods Cell Culture. The following cell lines and culture methods were used for all cell-based assays. SK-MEL-31 human skin cells and A204 human muscle cells were obtained from ATCC® and cultured and maintained in MoCoy-5A medium with 10% FBS and 1% penicillin and streptomycin. PANC-1 human pancreatic cancer cells were obtained from ATCC® and cultured and maintained in DMEM medium with 10% FBS and 1% penicillin and streptomycin.

[0102] Before plating in 96-well plates, cells were trypsinized and counted using a cell counter (Countess® Automated Cell Counter, Invitrogen). Cells were then suspended to the appropriate cell density for each cell type to be tested before seeding. Specifically, the cell suspension was assembled to contain 15,000 cells per 100 μL of cell medium for both SK-MEL-31 and A204 cells, and 12,000 cells per 100 μL of cell medium for PANC-1 cells. 100 μL of cell suspension was then seeded into each well of a white-walled tissue culture-treated 96-well plate (Corning) and maintained at 37° C. for 24 hours.

[0103] Cell Titer-Glo (CTG) ATP Assay. 24 hours after cell seeding, cells were dosed with 100 μL of a 1 / 3 dilution of 1 μM staurosporine (Sigma-Aldrich) and one of the following compositions using a Tecan D300e Digital Dispenser (Tecan); 100 μM synthetic sulforaphene / hydroxypropyl-β-cyclodextrin complex (compound 1); 17.5 μg / ml sulforaphene isolated from radish seed extract (compound 2) and 17.5 μg / ml positive control (compound 3). A total of nine sites were used for each cell line tested.

[0104] After cells were treated with test compounds for either 4 hours (data not shown), 48 hours or 72 hours, cells were left to stand at room temperature for approximately 30 minutes. Then, 100 μl of CellTiter-Glo Reagent (Promega) was added to each well of the plate, and each plate was mixed on an orbital shaker for 2 minutes to induce cell lysis. After shaking, each plate was incubated at room temperature for 10 minutes to stabilize the luminescence signal. The signal was then read on an EnVision Multilabel Reader (Perkin Elmer) according to the manufacturer's protocol. The effect of each composition on mitochondrial function was determined based on the quantification of the ATP present in each well, whereby the amount of ATP present is directly proportional to the amount of cells present in each well. Specifically, the effect of each compound was calculated using the following formula: Effect %=(X-control medium only) / (control-control DMSO effect)×100%.

[0105] Example 2: Stable sulforaphene results in increased mitochondrial ATP production in skin cells To determine whether stabilized sulforaphene (i.e., synthetic sulforaphene / hydroxypropyl-β-cyclodextrin complex) can treat mitochondrial disorders of the skin, such as psoriasis, or skin aging, the CellTiter-Glo® Luminescent Cell Viability Assay was performed on SK-MEL-31 human skin cells, as described above. The assay determined the number of viable skin cells present in each well by measuring the amount of ATP present in each well. Briefly, detection was based on measuring the amount of ATP present from viable cells using a luciferase reaction. If mitochondrial function (i.e., ATP generation from oxidative phosphorylation) is increased after administration of the stabilized sulforaphene when compared to cells treated with staurosporine alone, the exemplary stabilized sulforaphene composition can be used to treat mitochondrial disorders of the skin.

[0106] Staurosporine (STSP) is a cell-permeable alkaloid isolated from Streptomyces staurosporeus. Staurosporine is a potent nonselective inhibitor of protein kinases (including protein kinase C), and it induces apoptosis in cells. Therefore, cells treated with staurosporine alone were used as a negative control.

[0107] Following treatment with STSP, SK-MEL-31 human skin cells were dosed with 100 μM synthetic sulforaphene / hydroxypropyl-β-cyclodextrin complex (compound 1), 17.5 μg / mL sulforaphene isolated from radish seed extract (compound 2), or 17.5 μg / mL positive control (compound 3) and incubated for either 4 h (data not shown), 48 h, or 72 h, as shown in Figures 1A-1B.

[0108] The data shown in Figures 1A-1B indicate that both compounds containing stabilized sulforaphene (i.e., Compound 1 and Compound 2) caused an increase in ATP generation in skin cells after treatment with STSP that was comparable to that shown after treatment with the positive control compound (Compound 3). Thus, the stabilized sulforaphene compositions of the present disclosure are shown to increase mitochondrial function by increasing oxidative phosphorylation and ATP generation in vitro. Taken together, these data indicate that the stabilized sulforaphene compositions of the present disclosure can be used to treat mitochondrial disorders of the skin, such as psoriasis and skin aging.

[0109] Example 3: Stable sulforaphene results in increased mitochondrial ATP production in muscle cells To determine whether stabilized sulforaphene (i.e., synthetic sulforaphene / hydroxypropyl-β-cyclodextrin complex) can treat mitochondrial myopathy in muscle tissue (e.g., chronic fatigue syndrome (CFS), essential tremor, or Parkinson's), a CellTiter-Glo® Luminescent Cell Viability Assay was performed on A204 human muscle cells, as described above. The experiment was performed as shown in Example 2 (above). Thus, if mitochondrial function (i.e., ATP generation from oxidative phosphorylation) is increased following administration of stable sulforaphene when compared to cells treated with staurosporine alone, then the exemplary stabilized sulforaphene composition can be used to treat muscle mitochondrial myopathy.

[0110] Following treatment with STSP, A204 human muscle cells were dosed with 100 μM synthetic sulforaphene / hydroxypropyl-β-cyclodextrin complex (compound 1), 17.5 μg / mL sulforaphene isolated from radish seed extract (compound 2), or 17.5 μg / mL positive control (compound 3) and incubated for either 4 h (data not shown), 48 h, or 72 h, as shown in Figures 2A-2B.

[0111] The data shown in Figures 2A-2B indicate that both compounds containing stabilized sulforaphene (i.e., Compound 1 and Compound 2) caused an increase in ATP production in muscle cells after treatment with STSP that was comparable to that shown after treatment with the positive control compound (Compound 3). Thus, the stabilized sulforaphene compositions of the present disclosure are shown to increase mitochondrial function by increasing oxidative phosphorylation and ATP production in vitro. Taken together, these data indicate that the stabilized sulforaphene compositions of the present disclosure can be used to treat mitochondrial myopathies (e.g., CFS and essential tremor).

[0112] Example 4: Stable sulforaphene results in increased mitochondrial ATP production in other (pancreatic) cells To determine whether stabilized sulforaphene (i.e., synthetic sulforaphene / hydroxypropyl-β-cyclodextrin complex) can treat mitochondrial disorders in other cell types (e.g., pancreas to modulate endocrine function), a CellTiter-Glo® Luminescent Cell Viability Assay was performed on PANC-1 human pancreatic cells, as described above. Experiments were performed as shown in Examples 2 and 3 (above). Thus, if mitochondrial function (i.e., ATP generation from oxidative phosphorylation) is increased following administration of stable sulforaphene when compared to cells treated with staurosporine alone, the exemplary stabilized sulforaphene composition can be used to treat mitochondrial disorders from other organs or hormone-based, such as PCOS, prostatic myopathy, and thyroid disorders.

[0113] Here, as in Examples 2 and 3, following treatment with STSP, PANC-1 cells were dosed with 100 μM synthetic sulforaphene / hydroxypropyl-β-cyclodextrin complex (compound 1), 17.5 μg / mL sulforaphene isolated from radish seed extract (compound 2), or 17.5 μg / mL positive control (compound 3) and incubated for either 4 hours (data not shown), 48 hours, or 72 hours.

[0114] The data shown in Figures 3A-3B indicate that both compounds containing stabilized sulforaphene (i.e., Compound 1 and Compound 2) caused an increase in ATP production in pancreatic cells following treatment with STSP that was comparable to that shown following treatment with the positive control compound (Compound 3). Thus, the stabilized sulforaphene compositions of the present disclosure are shown to increase mitochondrial function by increasing oxidative phosphorylation and ATP production in vitro. Taken together, these data indicate that the stabilized sulforaphene compositions of the present disclosure may be used to treat mitochondrial disorders in other tissues, such as the pancreas.

Claims

[Claim 1] The invention described in this specification.

Images